For the Inventor, By the Inventor

Enter assignee name

Boehringer Ingelheim (Canada) Ltd.

Calculating rank

USPTO Granted Patents = 62

% Expired Patents = 3.2

Forward Citations = 1,431

Loading Chart...

Loading Chart...

67 inventors (with patents filed for the assignee):

Youla S Tsantrizos (16 out of 37 patents)

Nathalie Goudreau (16 out of 25 patents)

Jean Rancourt (15 out of 39 patents)

4. Montse Llinas-Brunet (14 out of 35 patents)

5. Murray D Bailey (14 out of 35 patents)

6. Dale R Cameron (12 out of 27 patents)

7. Pierre Louis Beaulieu (12 out of 45 patents)

8. Teddy Halmos (12 out of 28 patents)

9. George Kukolj (12 out of 16 patents)

10. Marc-Andre Poupart (11 out of 21 patents)

11. Elise Ghiro (11 out of 21 patents)

12. William W Ogilvie (11 out of 12 patents)

13. Dominik M Wernic (11 out of 13 patents)

14. Anne-Marie Faucher (11 out of 20 patents)

15. Christiane Yoakim (10 out of 44 patents)

Core Competencies:

Hepatitis C

Polymerase Inhibitors

Viral Inhibitors

Tri-Peptides

Papillomavirus

RNA Molecules

Protease Assays

Non-Nucleoside Inhibitors

Antiherpes Peptides

Azetidinone Derivatives

Enzymatic Resolution

ATPase Activity

62 patents: Sort by Forward Citations

1. 7919312 - Self-replicating RNA molecule from hepatitis C virus (2011-04-05),

2. RE42164 - Hepatitis C inhibitor tri-peptides (2011-02-21),

3. 7893084 - Viral polymerase inhibitors (2011-02-22),

4. 7838207 - Surrogate cell-based system and method for assaying the activity of hepatitis C virus NS3 protease (2010-11-23),

5. RE41894 - Hepatitis C inhibitor tri-peptides (2010-10-25),

6. 7807670 - Inhibitors of papilloma virus (2010-10-05),

7. RE41356 - Hepatitis C inhibitor tri-peptides (2010-05-24),

8. 7576079 - Viral polymerase inhibitors (2009-08-18),

9. 7528167 - Inhibitors of papilloma virus (2009-05-05),

10. 7439258 - Viral polymerase inhibitors (2008-10-21),

11. RE40525 - Hepatitis C inhibitor tri-peptides (2008-09-29),

12. 7344723 - Self-replicating RNA molecule from hepatitis C virus (2008-03-18),

13. 7323567 - RSV polymerase inhibitors (2008-01-29),

14. 7294457 - Direct binding assay for identifying inhibitors of HCV polymerase (2007-11-13),

15. 7276373 - Surrogate cell-based system and method for assaying the activity of hepatitis C virus NS3 protease (2007-10-02),

Company Overview

Boehringer Ingelheim (Canada) Ltd. is a prominent player in the pharmaceutical sector, focusing on the development of innovative viral inhibitors. The company specializes in addressing critical health challenges associated with viral infections, particularly in the realm of Hepatitis C. Its research encompasses a range of core technologies, including polymerase inhibitors, protease assays, and non-nucleoside inhibitors. Located in Laval, Canada, Boehringer Ingelheim is committed to advancing therapeutic solutions that enhance patient outcomes and contribute to global health advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

62 Patents

#1 in Laval

#217 in Canada

#11,779 in the World

Boehringer Ingelheim (Canada) Ltd.

Forward Citations = 1,431

67 inventors:

Youla S Tsantrizos (16 out of 37 patents)

Nathalie Goudreau (16 out of 25 patents)

Jean Rancourt (15 out of 39 patents)

4. Montse Llinas-Brunet (14 out of 35 patents)

5. Murray D Bailey (14 out of 35 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Boehringer Ingelheim (Canada) Ltd.. Retrieved from https://idiyas.com/company/boehringer-ingelheim-canada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…